INDIANAPOLIS, May 29, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved Cyramza® (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib, for…Original Article
Lilly’s Cyramza (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
